Immunohistochemical Analysis of Survivin Expression in Primary Breast Cancers

Survivin, an inhibitor of apoptosis, is expressed in fetal tissues but undetectable in normal adult tissues. It is also expressed in most common human cancers. This study evaluated the expression of survivin in breast cancers. A monoclonal anti-survivin antibody B1 was generated. Immunohistochemical...

Full description

Saved in:
Bibliographic Details
Published inJournal of the Formosan Medical Association Vol. 103; no. 12; pp. 925 - 931
Main Authors Chu, Jan-Show, Shew, Jin-Yuh, Huang, Chiun-Sheng
Format Journal Article
LanguageEnglish
Published Singapore 臺灣醫學會 01.12.2004
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Survivin, an inhibitor of apoptosis, is expressed in fetal tissues but undetectable in normal adult tissues. It is also expressed in most common human cancers. This study evaluated the expression of survivin in breast cancers. A monoclonal anti-survivin antibody B1 was generated. Immunohistochemical staining was performed in 226 paraffin sections of primary breast cancers and correlated with the patients' clinicopathological characteristics. Survivin was expressed in the cytoplasm of tumor cells in 59.3% of breast cancers. Expression of survivin was associated with high histologic grade (p = 0.027), high mitotic count (p = 0.014), positive p53 immunostaining (p = 0.012), neu overexpression (p = 0.018), and with bcl-2 (p = 0.001) and bak (p < 0.001) expression. No correlation was found between survivin expression and age, tumor size, estrogen receptor, progesterone receptor or Bax expression. Survivin expression was not significantly associated with overall or disease-free survival. Survivin expression is correlated with high histologic grade, high mitotic count, p53 overexpression, and bcl-2 expression in breast cancer. It does not have significance as a marker in predicting overall or disease-free survival.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0929-6646
DOI:10.29828/JFMA.200412.0007